Hence, AAV6-RNAi-mediated inhibitions of MMP3 and MMP13 along with inhibitions of ADAMTS4 and ADAMTS5 enhancing collagen II and aggrecan, could be promising long-term strategies for less immunogenic biological treatments in DDD. Here, MMP3 is linked to Dowling-Degos disease 1.